JP2002539827A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002539827A5 JP2002539827A5 JP2000608744A JP2000608744A JP2002539827A5 JP 2002539827 A5 JP2002539827 A5 JP 2002539827A5 JP 2000608744 A JP2000608744 A JP 2000608744A JP 2000608744 A JP2000608744 A JP 2000608744A JP 2002539827 A5 JP2002539827 A5 JP 2002539827A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- nos
- polypeptide
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000040430 polynucleotide Human genes 0.000 description 88
- 108091033319 polynucleotide Proteins 0.000 description 88
- 239000002157 polynucleotide Substances 0.000 description 88
- 229920001184 polypeptide Polymers 0.000 description 72
- 102000004196 processed proteins & peptides Human genes 0.000 description 72
- 108090000765 processed proteins & peptides Proteins 0.000 description 72
- 230000000295 complement effect Effects 0.000 description 48
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 32
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 32
- 125000003275 alpha amino acid group Chemical group 0.000 description 16
- 239000002269 analeptic agent Substances 0.000 description 16
- 230000037430 deletion Effects 0.000 description 16
- 238000012217 deletion Methods 0.000 description 16
- 230000028993 immune response Effects 0.000 description 16
- 238000003780 insertion Methods 0.000 description 16
- 230000037431 insertion Effects 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27626899A | 1999-03-25 | 1999-03-25 | |
| US09/276,268 | 1999-03-25 | ||
| US09/383,586 | 1999-08-26 | ||
| US09/383,586 US6242419B1 (en) | 1999-03-25 | 1999-08-26 | Compositions isolated from stromal cells and methods for their use |
| PCT/NZ2000/000015 WO2000058463A1 (en) | 1999-03-25 | 2000-02-18 | Polynucleotide and deduced amino acid sequences from stromal cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002539827A JP2002539827A (ja) | 2002-11-26 |
| JP2002539827A5 true JP2002539827A5 (enExample) | 2007-04-05 |
Family
ID=26957887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000608744A Abandoned JP2002539827A (ja) | 1999-03-25 | 2000-02-18 | 間質細胞由来のポリヌクレオチド配列および推定アミノ酸配列 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6242419B1 (enExample) |
| EP (1) | EP1163334A4 (enExample) |
| JP (1) | JP2002539827A (enExample) |
| CN (1) | CN1358228A (enExample) |
| AU (1) | AU782974B2 (enExample) |
| CA (1) | CA2368477A1 (enExample) |
| HK (1) | HK1048137A1 (enExample) |
| NZ (1) | NZ514329A (enExample) |
| WO (1) | WO2000058463A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020132252A1 (en) * | 1997-06-16 | 2002-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030143676A1 (en) * | 1999-03-25 | 2003-07-31 | Genesis Research And Development Corporation Limited | Fibroblast growth factor receptors and methods for their use |
| AU5887700A (en) * | 1999-10-19 | 2001-04-30 | Millennium Pharmaceuticals, Inc. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
| US6743907B1 (en) * | 1999-10-19 | 2004-06-01 | Lexicon Genetics Incorporated | Human proteins and polynucleotides encoding the same |
| US7348162B2 (en) * | 2000-03-22 | 2008-03-25 | Amgen Inc. | Nucleic acids encoding fibroblast growth factor receptor-like proteins and uses thereof |
| WO2001092495A2 (en) * | 2000-05-26 | 2001-12-06 | Millennium Pharmaceuticals, Inc. | A human lysyl ixodase (47765) and uses thereof |
| US6812002B2 (en) * | 2000-08-30 | 2004-11-02 | Pfizer Inc. | Osteoactivin protein and nucleic acids encoding the same, compositions and methods of stimulating bone differentiation |
| JP2002272470A (ja) * | 2001-03-21 | 2002-09-24 | Takashi Nakamura | リジルオキシダーゼ関連タンパク質をコードする核酸 |
| CA2489145A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | Insulin-sensitizing agent |
| CA2504443A1 (en) * | 2002-10-30 | 2004-05-13 | Pointilliste, Inc. | Methods for producing polypeptide-tagged collections and capture systems containing the tagged polypeptides |
| US20040241748A1 (en) * | 2003-02-10 | 2004-12-02 | Dana Ault-Riche | Self-assembling arrays and uses thereof |
| US20070275872A1 (en) * | 2003-10-28 | 2007-11-29 | Cooper Garth J | Peptides with Anti-Obesity Activity and Other Related Uses |
| US20050095648A1 (en) * | 2003-10-30 | 2005-05-05 | Mario Geysen | Method for designing linear epitopes and algorithm therefor and polypeptide epitopes |
| US20060018911A1 (en) * | 2004-01-12 | 2006-01-26 | Dana Ault-Riche | Design of therapeutics and therapeutics |
| US20090297479A1 (en) * | 2008-03-28 | 2009-12-03 | Kiyoshi Ariizumi | Dc-hil conjugates for treatment of t-cell disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001009327A2 (en) * | 1999-07-28 | 2001-02-08 | Genentech, Inc. | Method of preventing the injury or death of retinal cells and treating ocular diseases |
| WO1999063088A2 (en) | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Membrane-bound proteins and nucleic acids encoding the same |
| AU4688499A (en) | 1998-10-23 | 2000-05-15 | Human Genome Sciences, Inc. | Fibroblast growth factor receptor-5 |
| WO2001053455A2 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| AU2495200A (en) * | 1999-03-08 | 2000-09-28 | Genentech Inc. | Compositions and methods for the treatment of tumor |
| AU3774300A (en) * | 1999-06-02 | 2000-12-18 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU5907800A (en) * | 1999-06-30 | 2001-01-31 | Millennium Pharmaceuticals, Inc. | Membrane-associated and secreted proteins and uses thereof |
| EP1242443A4 (en) * | 1999-12-23 | 2005-06-22 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
| CA2400034A1 (en) * | 2000-02-17 | 2001-08-23 | Incyte Genomics, Inc. | Human kinases |
-
1999
- 1999-08-26 US US09/383,586 patent/US6242419B1/en not_active Expired - Fee Related
-
2000
- 2000-02-18 AU AU27021/00A patent/AU782974B2/en not_active Ceased
- 2000-02-18 JP JP2000608744A patent/JP2002539827A/ja not_active Abandoned
- 2000-02-18 CA CA002368477A patent/CA2368477A1/en not_active Abandoned
- 2000-02-18 HK HK03100235.2A patent/HK1048137A1/zh unknown
- 2000-02-18 NZ NZ514329A patent/NZ514329A/en unknown
- 2000-02-18 WO PCT/NZ2000/000015 patent/WO2000058463A1/en not_active Ceased
- 2000-02-18 EP EP00905487A patent/EP1163334A4/en not_active Withdrawn
- 2000-02-18 CN CN00807774A patent/CN1358228A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002539827A5 (enExample) | ||
| EP0865294B1 (en) | Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions | |
| KR970701776A (ko) | 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1) | |
| EP2479277A3 (en) | Compositions and methods of use for MGD-CSF in disease treatment | |
| WO2000021548A3 (en) | Angiogenically effective unit dose of fgf and method of administering | |
| US9782429B2 (en) | Formulation having mobilizing activity | |
| WO1999053051A3 (en) | 5' ests and encoded human proteins | |
| JP2002542827A5 (enExample) | ||
| JP2004511201A5 (enExample) | ||
| WO1999006554A3 (en) | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES | |
| JP2003515533A5 (enExample) | ||
| WO2002004623A3 (en) | ANTISENSE COMPOSITIONS TARGETED TO β1 ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE | |
| WO1999040197A3 (en) | Variants of the angiogenic factor vascular endothelial cell growth factor: vegf | |
| JP2001520238A (ja) | 低毒性のヒトインターフェロン−αアナログ | |
| JP2002527401A5 (enExample) | ||
| JP2002527354A5 (enExample) | ||
| JP2005506275A5 (enExample) | ||
| JP2004527551A5 (enExample) | ||
| RU2003119657A (ru) | Новые факторы роста фибробластов | |
| WO2003034996A3 (en) | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment | |
| NZ516477A (en) | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders | |
| JP2001522810A5 (enExample) | ||
| WO1997048411A1 (en) | Medicinal compositions for treating liver diseases | |
| JP2003514025A5 (enExample) | ||
| KR970701724A (ko) | 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin) |